Ventyx Biosciences Reports Positive Phase 2 Data for Oral NLRP3 Inhibitor VTX3232 in Obesity and Cardiovascular Risk

Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences ...